Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application
PLGA
CD64
DOI:
10.2147/ijn.s68440
Publication Date:
2014-10-24T00:44:00Z
AUTHORS (5)
ABSTRACT
Background: Rheumatoid arthritis (RA) is an autoimmune disease with severe consequences for the quality of life sufferers. Regrettably, inflammatory process involved remains unclear, and finding successful therapies as well new means its early diagnosis have proved to be daunting tasks. As macrophages are strongly associated RA inflammation, effective therapy may encompass ability target these cells. In this work, a approach targeted imaging was developed based on use multifunctional polymeric nanoparticles. Methods: Poly(lactic-co-glycolic acid) nanoparticles were prepared using single emulsion-evaporation method comprised co-association superparamagnetic iron oxide (SPIONs) methotrexate. The further functionalized antibody against macrophage-specific receptor, CD64, which overexpressed at sites RA. devised characterized mean particle size, polydispersity index, zeta potential, morphology, association SPIONs, methotrexate, anti-CD64 antibody. Lastly, cytotoxicity assessed in RAW 264.7 cells standard MTT LDH assays. Results: had diameter range 130–200 nm potential values ranging from -32 mV -16 mV. Association either methotrexate or SPIONs did not significantly affect properties Conjugation antibody, turn, caused slight increase size surface charge. Transmission electron microscopy confirmed within poly(lactic-co-glycolic matrix. Both by Fourier transform infrared spectroscopy, quantified yielding high 36% 79%, respectively. vitro toxicity studies methotrexate-loaded nanosystem more than free drug. Conclusion: Multifunctional anti-CD64-conjugated combined delivery successfully characterized. This has provide theranostic management Keywords: FcγRI, acid), nanoparticles, drug
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (13)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....